InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
June 28 2023 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company commercializing and developing anti-inflammatory
therapeutics that target the complement system, today announced the
appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of
InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with
extensive experience in the pharmaceutical industry, including
leadership roles in clinical development, medical affairs and
overseeing the launch of new drugs across multiple geographies. She
will be responsible for all clinical developments related to
InflaRx’s portfolio as she joins the C-suite of the company.
Prof. Niels C. Riedemann, Chief Executive
Officer and Founder of InflaRx, commented: “We are excited to
welcome Camilla to our team. She is a highly accomplished executive
who brings a wealth of expertise in drug development. At InflaRx,
she will lead our clinical development activities. Besides managing
our ongoing clinical trials, she will also drive the strategy for
future clinical development programs of the company including those
for vilobelimab and INF904. She will be a great addition to our
team as we bring our first product to market and advance our
development programs.”
Dr. Camilla Chong commented: "I am thrilled to
be joining InflaRx at this transformative stage for the Company
following the recent Emergency Use Authorization by the FDA and the
ongoing commercial launch of Gohibic (vilobelimab). I believe that
our innovative anti-C5a / anti-C5aR programs have the potential to
be truly life-changing for patients with acute inflammatory
conditions as well as many chronic immunologic diseases. I very
much look forward to advancing our clinical programs with the goal
of providing patients suffering from these diseases with improved
treatments that can truly impact their quality of life."
Dr. Chong is a medical doctor with 25 years of
experience in the global pharmaceutical industry. She has
successfully led clinical development, medical affairs, clinical
operations, regulatory and pharmacovigilance teams and has managed
global clinical development programs. She has extensive experience
in the launch of many new medicines in multiple geographies. She
joins InflaRx from Kyowa Kirin Corporation, where she was Vice
President & Global Medical Affairs Therapy Area Head -
Immunology. Her previous senior management roles have spanned
multiple therapeutic areas, including cardiology, immunology,
respiratory, dermatology and orphan diseases at Pfizer,
GlaxoSmithKline and Teva. Dr. Chong received her MD from the Royal
Free Hospital School of Medicine, University College London, UK.
She holds a Diploma in Pharmaceutical Medicine and is a Member of
the Faculty of Pharmaceutical Medicine (MFPM).
About InflaRx
InflaRx GmbH (Germany) and InflaRx
Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx
N.V. (together, “InflaRx”).
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a / C5aR technologies to discover and develop first-in-class
or best-in-class, potent and specific inhibitors of C5a and C5aR.
Complement C5a and its receptor C5aR are powerful inflammatory
mediators involved in the progression of a wide variety of
autoimmune and other inflammatory diseases. InflaRx was founded in
2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA. For further
information, please visit www.inflarx.de.
Contacts:
InflaRx
N.V.Email: IR@inflarx.de
MC Services AGKatja Arnold,
Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.euEurope:
+49 89-210 2280U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTSThis
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential” or “continue,” among others. Forward-looking statements
appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other
things, our ability to commercialize and the receptiveness of
Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19
patients and U.S. hospitals or our other product candidates; our
expectations regarding the size of the patient populations for,
market opportunity for, coverage and reimbursement for and clinical
utility of Gohibic (vilobelimab) in its approved or authorized
indication or for vilobelimab and any other product candidates,
under an EUA and in the future if approved for commercial use in
the U.S. or elsewhere; the success of our future clinical trials
for vilobelimab and any other product candidates and whether such
clinical results will reflect results seen in previously conducted
preclinical studies and clinical trials; the timing, progress and
results of clinical trials of our product candidates, and
statements regarding the timing of initiation and completion of
studies or trials and related preparatory work, the period during
which the results of the trials will become available, the costs of
such trials and our research and development programs generally;
our interactions with regulators regarding the results of clinical
trials and potential regulatory approval pathways, including
related to our BLA submission for Gohibic (vilobelimab), and our
ability to obtain and maintain full regulatory approval of
vilobelimab or Gohibic (vilobelimab) for any indication; whether
the FDA, the EMA, or any comparable foreign regulatory authority
will accept or agree with the number, design, size, conduct or
implementation of our clinical trials, including any proposed
primary or secondary endpoints for such trials; our expectations
regarding the scope of any approved indication for vilobelimab; our
ability to leverage our proprietary anti-C5a and C5aR technologies
to discover and develop therapies to treat complement-mediated
autoimmune and inflammatory diseases; our ability to protect,
maintain and enforce our intellectual property protection for
vilobelimab and any other product candidates, and the scope of such
protection; our manufacturing capabilities and strategy, including
the scalability and cost of our manufacturing methods and processes
and the optimization of our manufacturing methods and processes,
and our ability to continue to rely on our existing third-party
manufacturers and our ability to engage additional third-party
manufacturers for our planned future clinical trials and for
commercial supply of vilobelimab and for the finished product
Gohibic (vilobelimab); our estimates of our expenses, ongoing
losses, future revenue, capital requirements and our needs for or
ability to obtain additional financing; our ability to defend
against liability claims resulting from the testing of our product
candidates in the clinic or, if approved, any commercial sales; if
any of our product candidates obtain regulatory approval, our
ability to comply with and satisfy ongoing obligations and
continued regulatory overview; our ability to comply with enacted
and future legislation in seeking marketing approval and
commercialization; our future growth and ability to compete, which
depends on our retaining key personnel and recruiting additional
qualified personnel; and our competitive position and the
development of and projections relating to our competitors in the
development of C5a and C5aR inhibitors or our industry; and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in our periodic filings with the Securities Exchange
Commission. These statements speak only as of the date of this
press release and involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024